Nilotinib Accord

Nilotinib, the active ingredient in Nilotinib Accord, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It targets BCR‑ABL positive malignancies and is indicated for chronic myeloid leukemia in the chronic phase and Philadelphia chromosome‑positive acute lymphoblastic leukemia in adult patients.

GNH USA supplies Nilotinib Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory‑approved products to meet the needs of oncology treatment programs across multiple regions.

Nilotinib acts on the BCR‑ABL tyrosine‑kinase pathway and is used in specific hematologic cancers.

- Chronic Myeloid Leukemia (CML) in chronic phase: Nilotinib reduces leukemic cell proliferation, achieving cytogenetic and deep molecular responses, and is used when patients are resistant or intolerant to first‑line therapy. - Philadelphia chromosome‑positive Acute Lymphoblastic Leukemia (Ph+ ALL): Nilotinib provides targeted inhibition of BCR‑ABL, contributing to remission induction and maintenance in adult patients, often as part of combination regimens. - CML after imatinib resistance or intolerance: Nilotinib serves as a second‑generation BCR‑ABL inhibitor to achieve disease control and improve survival outcomes.

Nilotinib may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea - Diarrhea - Rash - Fatigue

Serious or Rare Side Effects: - QT interval prolongation - Pancreatitis - Severe elevation of liver enzymes

When prescribing nilotinib, clinicians should observe several precautionary measures to minimize risk. - Cardiac monitoring: Perform baseline ECG and monitor QT interval during therapy. - Hematologic monitoring: Regularly check complete blood counts for neutropenia or thrombocytopenia. - Hepatic monitoring: Assess liver function tests before and throughout treatment. - Drug interaction vigilance: Avoid concomitant strong CYP3A4 inhibitors and QT‑prolonging agents. - Dose adjustment: Reduce dose in patients with moderate hepatic impairment. - Store at room temperature: Keep tablets in the original container, protect from moisture and light.

Nilotinib interacts with several medicines that can alter its plasma concentration or cardiac safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase nilotinib exposure. - QT‑prolonging drugs (e.g., sotalol, amiodarone): raise risk of cardiac arrhythmias. - Antacids containing aluminum or magnesium: reduce nilotinib absorption.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., fluconazole): may require dose adjustment. - CYP3A4 inducers (e.g., rifampin, St. John’s wort): can lower nilotinib levels and reduce efficacy.